Trending Tickers: 22nd Century Group, Inc. (NYSEMKT:XXII), Synthetic Biologics Inc. (NYSEMKT:SYN), Conatus Pharmaceuticals Inc. (NASDAQ:CNAT), Ruby Tuesday, Inc. (NYSE:RT)

22nd Century Group, Inc. (NYSEMKT:XXII) belongs to Healthcare sector. Its weekly performance is -11.29%. On last trading day company shares ended up $0.82. 22nd Century Group, Inc. (NYSEMKT:XXII) distance from 50-day simple moving average (SMA50) is -17.99%. Zacks upgraded shares of 22nd Century Group, Inc. (NYSEMKT:XXII) from a sell rating to a hold rating in a research report released on Monday morning.

Synthetic Biologics Inc. (NYSEMKT:SYN) shares increased 6.67% in last trading session and ended the day at $3.04. SYN return on assets is -242.70%. Synthetic Biologics Inc. (NYSEMKT:SYN) quarterly performance is 43.40%. Synthetic Biologics Inc. (NYSEMKT:SYN) reported the initiation of a Phase 2 clinical trial of its proprietary SYN-010 for the treatment of irritable bowel syndrome with constipation (IBS-C). This is a placebo-controlled study to evaluate the ability of two dose strengths of SYN-010 to reduce the production of methane in breath methane-positive patients with IBS-C. Breath methane is strongly associated with constipation in IBS-C and higher methane levels are proportional to constipation severity.

Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) ended the last trading day at $4.83. Company weekly volatility is calculated as 4.96% and price to cash ratio as 3.07. Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) showed a weekly performance of -6.40%. On 25 June, Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) announced pre-treatment biomarker and histology data from the first 16 patients enrolled in the company’s Phase 2b clinical trial of its lead drug candidate, emricasan, in post-orthotopic liver transplant (POLT) recipients. These patients have reestablished liver fibrosis or cirrhosis post-transplant as a result of recurrent hepatitis C virus (HCV) infection and have successfully achieved a sustained viral response (SVR) following HCV antiviral therapy (POLT-HCV-SVR).

Ruby Tuesday, Inc. (NYSE:RT) shares increased 5.25% in last trading session and ended the day at $6.62. RT Gross Margin is 17.20% and its return on assets is -0.80%. Ruby Tuesday, Inc. (NYSE:RT) quarterly performance is -2.07%.Ruby Tuesday, Inc. (NYSE:RT) said that, it will release results for its fiscal fourth quarter after the close of financial markets on Thursday, July 23, 2015 which will be followed by a conference call to review its financial results at 5:00 p.m. Eastern time.

Leave a Reply

Your email address will not be published. Required fields are marked *